Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sviridenko

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
PET Clinics|March 29, 2023
Imaging FibrosisAnna Sviridenko, Gianpaolo di Santo, Irene Virgolini
Theranostics|January 22, 2024
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2023
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid CancerElisabeth von Guggenberg, Christian Uprimny, Maximilian Klinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Cholecystokinin-2 receptor targeting by [<sup>68</sup>Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancerGianpaolo Di Santo, Giulia Santo, Vladan Martinovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Diagnostic Performance of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsChristian Uprimny, Elisabeth von Guggenberg, Anna Sviridenko, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 3, 2024
Efficacy and safety of rechallenge with [<sup>177</sup>Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancerGiulia Santo, Gianpaolo Di Santo, Anna Sviridenko, et al.
Clinical Nuclear Medicine|October 18, 2022
Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CTAnna Sviridenko, Anna Boehm, Gianpaolo di Santo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Safety, Biodistribution, and Radiation Dosimetry of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsElisabeth von Guggenberg, Gianpaolo di Santo, Christian Uprimny, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
PET Clinics|March 29, 2023
Imaging FibrosisAnna Sviridenko, Gianpaolo di Santo, Irene Virgolini
Theranostics|January 22, 2024
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2023
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid CancerElisabeth von Guggenberg, Christian Uprimny, Maximilian Klinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Cholecystokinin-2 receptor targeting by [<sup>68</sup>Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancerGianpaolo Di Santo, Giulia Santo, Vladan Martinovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Diagnostic Performance of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsChristian Uprimny, Elisabeth von Guggenberg, Anna Sviridenko, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 3, 2024
Efficacy and safety of rechallenge with [<sup>177</sup>Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancerGiulia Santo, Gianpaolo Di Santo, Anna Sviridenko, et al.
Clinical Nuclear Medicine|October 18, 2022
Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CTAnna Sviridenko, Anna Boehm, Gianpaolo di Santo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Safety, Biodistribution, and Radiation Dosimetry of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsElisabeth von Guggenberg, Gianpaolo di Santo, Christian Uprimny, et al.
Pageof 1